Home » MEDTRONIC RECEIVES FDA APPROVAL FOR ITS CONCERTO/VIRTUOSO LINE OF IMPLANTABLE CARDIAC DEVICES

MEDTRONIC RECEIVES FDA APPROVAL FOR ITS CONCERTO/VIRTUOSO LINE OF IMPLANTABLE CARDIAC DEVICES

May 17, 2006

Medtronic Inc. announced that it received FDA approval of its Concerto/Virtuoso line of implantable cardiac devices, its next generation of cardiac rhythm disease management products.
Trading Markets Live

KEYWORDS FDAnews Device Daily Bulletin

15Apr
Five Telltale Signs You’re Ready for an Electronic TMF System
21Apr
CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health
26Apr
MAGI's Clinical Research vConference — Spring 2021
06May
The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

MEDTRONIC RECEIVES FDA APPROVAL FOR ITS CONCERTO/VIRTUOSO LINE OF IMPLANTABLE CARDIAC DEVICES

Upcoming Events

Five Telltale Signs You’re Ready for an Electronic TMF System

CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

MAGI's Clinical Research vConference — Spring 2021

The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Roche Receives CE Mark for Elecsys Cancer Test

Biogen and Bio-Thera Solutions Partner Over Actemra Biosimilar

Former Indivor Executive Seeks FDA Hearing to Avoid Debarment

FDA Clears Activ Surgical’s Imaging Module for ActivEdge Platform

The Revised ICH E8: A Guide to New Clinical Trial Requirements